← Shanghai ZJ Bio-Tech Co. Ltd. A overview

Shanghai ZJ Bio-Tech Co. Ltd. A vs Imeik Technology Development: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai ZJ Bio-Tech Co. Ltd. A (688317.CG)

Q3 202620 Jul – 9 Oct 2026

▲2▼1

ZJ Bio-Tech: product approvals build pipeline, but losses widen

New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.
These approvals are the main positive catalysts that could drive future sales and investor optimism.
Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.
The widening loss is the key fundamental negative that pressures the share price.
Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.
Buybacks are a capital action that can cushion the stock and show insider confidence.

August 202620 Jul – 9 Oct 2026

▲2▼1

ZJ Bio-Tech: product approvals build pipeline, but losses widen

New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.
These approvals are the main positive catalysts that could drive future sales and investor optimism.
Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.
The widening loss is the key fundamental negative that pressures the share price.
Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.
Buybacks are a capital action that can cushion the stock and show insider confidence.

Latest20 Jul – 9 Oct 2026

▲2▼1

ZJ Bio-Tech: product approvals build pipeline, but losses widen

New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.
These approvals are the main positive catalysts that could drive future sales and investor optimism.
Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.
The widening loss is the key fundamental negative that pressures the share price.
Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.
Buybacks are a capital action that can cushion the stock and show insider confidence.

Imeik Technology Development Co (300896.CS)

Q3 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

August 202615 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.

Latest15 Jul – 28 Sep 2026

▼3▲1

Imeik profit slumps as costs surge; new product approvals offer offset

First-half profit and sales both fell sharply Imeik's first-half revenue fell 6.42% to 1.216 billion yuan and net profit dropped 24.84% to 593 million yuan. Selling expenses jumped 63%, squeezing margins. Core injectable products shrank, so the market sees weaker earnings power and marks the stock down.
The half-year earnings miss is the main force weighing on the stock this period.
Goodwill risk from the REGEN acquisition Goodwill of 1.641 billion yuan sits on the balance sheet, 1.305 billion of it from buying South Korea's REGEN. If that business underperforms, the company must write it down, which would hit reported profit again. This adds uncertainty on top of the earnings decline.
It is a concrete balance-sheet risk that can hurt future profit and investor confidence.
New product approvals broaden the product line Imeik won approval for a sodium hyaluronate gel medical device and, in September, a lidocaine-tetracaine numbing cream used in filler and laser procedures. These add sellable products and support future revenue, though they take time to contribute meaningfully.
Approvals are the clearest positive counterweight to the weak earnings.
Botulinum toxin still not launched Imeik said its botulinum toxin product is not yet on sale, with the sales team only doing pre-launch work. This delays a much-anticipated new growth driver, so expected future revenue from it keeps getting pushed out.
A delayed key product launch removes a hoped-for growth catalyst.